This post was originally published on News-medical.net
You will shortly be re-directed to the publisher's website
Researchers from Mass General Brigham and collaborators found that use of GLP-1 drugs to treat obesity more than doubled from 2022 to 2023 while rates of surgery dropped by one quarter.